Overview

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

Status:
Completed
Trial end date:
2016-05-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes. Both treatments will be given (separately) to all subjects as a one-time loading dose (i.e. higher than a normal daily dose), followed by daily dose for the next 5 to 7 days. Effectiveness of treatment will be measured with specialized blood tests before the loading dose, at two time-points after the loading dose, and once after the last daily dose.
Phase:
Phase 4
Details
Lead Sponsor:
Juan J Badimon
Collaborator:
AstraZeneca
Treatments:
Aspirin
Clopidogrel
Ticagrelor
Ticlopidine